Literature DB >> 12243218

Karnofsky Performance Status Assessment: resident versus attending.

Benny J Liem1, John M Holland, Matt Y Kang, S Christopher Hoffelt, Carol M Marquez.   

Abstract

BACKGROUND: Karnofsky Performance Status (KPS) is a commonly used scale to assess a patient's functional status.
METHODS: Between September 1999 and March 2000, 117 patients were independently evaluated and assigned KPS scores by both an attending physician and a resident physician at the time of radiation therapy simulation.
RESULTS: Both attending and resident median assigned KPS score was 80. Attending and resident KPS scores were identical for 50 patients (43%). When KPS scores differed, this difference was of the smallest incremental value (10 points) in 50 patients (75%). The Pearson correlation coefficient is 0.85, significant at the 0.01 level.
CONCLUSION: KPS scoring by radiation oncology attending physicians is similar to that by resident physicians.

Entities:  

Mesh:

Year:  2002        PMID: 12243218     DOI: 10.1080/08858190209528821

Source DB:  PubMed          Journal:  J Cancer Educ        ISSN: 0885-8195            Impact factor:   2.037


  10 in total

1.  Patient Functional Status at Transplant and Its Impact on Posttransplant Survival of Adult Deceased-donor Kidney Recipients.

Authors:  Kevin Bui; Vikram Kilambi; James R Rodrigue; Sanjay Mehrotra
Journal:  Transplantation       Date:  2019-05       Impact factor: 4.939

2.  Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.

Authors:  Viviana Londero; Massimo Bazzocchi; Chiara Del Frate; Fabio Puglisi; Carla Di Loreto; Giuliana Francescutti; Chiara Zuiani
Journal:  Eur Radiol       Date:  2004-02-18       Impact factor: 5.315

3.  Simple measures of function and symptoms in hospitalized heart failure patients predict short-term cardiac event-free survival.

Authors:  Evanthia Zaharias; Janine Cataldo; Lynda Mackin; Jill Howie-Esquivel
Journal:  Nurs Res Pract       Date:  2014-02-09

4.  Re-irradiation alternatives for recurrent high-grade glioma.

Authors:  Yuanli Dong; Chengrui Fu; Hui Guan; Tianyi Zhang; Zicheng Zhang; Tao Zhou; Baosheng Li
Journal:  Oncol Lett       Date:  2016-08-01       Impact factor: 2.967

5.  Using Novel Technology to Determine Mobility Among Hospitalized Heart Failure Patients: A Pilot Study.

Authors:  Jill Howie-Esquivel; Evanthia Zaharias
Journal:  Cardiol Res       Date:  2013-03-08

Review 6.  The Traditional Chinese Medicine Kangai Injection as an Adjuvant Method in Combination with Chemotherapy for the Treatment of Breast Cancer in Chinese Patients: A Meta-Analysis.

Authors:  Jing-Xian Xue; Zhi-Yuan Zhu; Wei-He Bian; Chang Yao
Journal:  Evid Based Complement Alternat Med       Date:  2018-04-18       Impact factor: 2.629

7.  Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals.

Authors:  Faisal Azam; Muhammad Farooq Latif; Ayesha Farooq; Syed Hammad Tirmazy; Saad AlShahrani; Shahid Bashir; Nedal Bukhari
Journal:  Case Rep Oncol       Date:  2019-09-25

8.  Karnofsky Performance Scale validity and reliability of Turkish palliative cancer patients

Authors:  Nagihan Yıldız Çeltek; Mustafa Süren; Osman Demir; İsmail Okan
Journal:  Turk J Med Sci       Date:  2019-06-18       Impact factor: 0.973

9.  Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.

Authors:  Peng Du; Hongyi Chen; Li Shen; Xiao Liu; Xuefan Wu; Lang Chen; Aihong Cao; Daoying Geng
Journal:  Curr Oncol       Date:  2022-09-17       Impact factor: 3.109

10.  Analysis of Key Clinical Variables and Radiological Manifestations Associated with the Treatment Response of Patients with Brain Metastases to Stereotactic Radiosurgery.

Authors:  Peng Du; Hongyi Chen; Li Shen; Xiao Liu; Jiawei Chen; Xuefan Wu; Tonggang Yu; Daoying Geng
Journal:  J Clin Med       Date:  2022-08-03       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.